| | Clinical Factors | Late TLR(-) | Late TLR(+) | P | | | (335 patients) | (19 patients) | |
| | Age (years old) | 65.5±10.3 | 62.8±11.2 | 0.272 | | BMI (kg/m2) | 24.9±2.9 | 24.3±2.8 | 0.429 | | Male sex, n (%) | 249 (74.3) | 16 (84.2) | 0.488 | | Previous PCI, n (%) | 33 (9.9) | 5 (26.3) | 0.061 | | Diabetes mellitus, n (%) | 108 (32.2) | 6 (31.6) | 1.000 | | Hypertension, n (%) | 232 (69.3) | 14 (73.7) | 0.879 | | CRF, n (%) | 129 (38.5) | 8 (42.1) | 0.811 | | Dyslipidemia, n (%) | 213 (63.6) | 12 (63.2) | 1.000 | | Current smoking, n (%) | 87 (26.0) | 8 (42.1) | 0.201 | | FHx of CAD, n (%) | 44 (13.1) | 0 (0) | 0.223 | | LV ejection fraction (%) | 60.2±8.4 | 62.5±6.9 | 0.300 | | Clinical diagnosis | | | 0.632 | | (i) Silent ischemia, n (%) | 19 (5.7) | 2 (10.5) | | | (ii) Stable angina, n (%) | 197 (58.8) | 12 (63.2) | | | (iii) Unstable angina, n (%) | 67 (20.0) | 4 (21.1) | | | (iv) STEMI, n (%) | 21 (6.3) | 1 (5.3) | | | (v) NSTEMI, n (%) | 31 (9.3) | 0 (0.0) | | | Multi Vessel disease, n (%) | 245 (73.1) | 10 (52.6) | 0.066 |
| | Laboratory tests | | | |
| | WBC (109/L) | 6.9±2.4 | 7.4±2.2 | 0.354 | | Hemoglobin (g/dl) | 13.6±1.8 | 13.7±2.0 | 0.840 | | Creatinine(mg/dl) | 1.04±0.43 | 1.19±0.63 | 0.303 | | GFR(ml/min/1.73m2) | 70.9±24.1 | 69.6±24.4 | 0.864 | | Total cholesterol (mg/dl) | 157±38 | 157±44 | 0.982 | | Triglyceride (mg/dl) | 141±88 | 118±38 | 0.283 | | LDL (mg/dl) | 97±35 | 102±38 | 0.576 | | HDL (mg/dl) | 42±11 | 39±8 | 0.277 | | CRP (mg/dl) | 0.34±0.92 | 1.44±3.27 | 0.200 |
| | Medication at discharge | | | |
| | (i) Aspirin, n (%) | 334 (99.7) | 19 (100.0) | 1.000 | | (ii) Clopidogrel, n (%) | 334 (99.7) | 19 (100.0) | 1.000 | | (iii) DAPT, n (%)# | 333 (99.4) | 19 (100.0) | 1.000 | | (vi) Beta blocker, n (%) | 237 (70.7) | 14 (73.7) | 1.000 | | (v) Statin, n (%) | 318 (94.9) | 19 (100.0) | 0.612 | | (vi) CCB, n (%) | 66 (19.7) | 9 (47.4) | 0.008 | | (vii) ACEI, n (%) | 82 (24.5) | 3 (15.8) | 0.581 | | (viii) ARB, n (%) | 128 (38.2) | 6 (31.6) | 0.634 |
| | Medication at first follow-up | | | |
| | (i) Aspirin, n (%) | 332 (99.1) | 19 (100.0) | 1.000 | | (ii) Clopidogrel, n (%) | 328 (97.9) | 18 (94.7) | 0.360 | | (iii) DAPT, n (%)# | 325 (97.0) | 18 (94.7) | 0.460 | | (vi) Beta blocker, n (%) | 252 (75.2) | 14 (73.7) | 1.000 | | (v) Statin, n (%) | 333 (99.4) | 19 (100.0) | 1.000 | | (vi) CCB, n (%) | 72 (21.5) | 7 (36.8) | 0.153 | | (vii) ACEI, n (%) | 35 (10.4) | 1 (5.3) | 0.706 | | (viii) ARB, n (%) | 136 (40.6) | 9 (47.4) | 0.634 |
| | Medication at second follow-up | | | |
| | (i) Aspirin, n (%) | 307 (91.6) | 17 (89.5) | 0.669 | | (ii) Clopidogrel, n (%) | 282 (84.2) | 18 (94.7) | 0.329 | | (iii) DAPT, n (%)# | 256 (76.4) | 16 (84.2) | 0.581 | | (vi) Beta blocker, n (%) | 244 (72.8) | 12 (63.2) | 0.429 | | (v) Statin, n (%) | 330 (98.5) | 19 (100.0) | 1.000 | | (vi) CCB, n (%) | 62 (18.5) | 6 (31.6) | 0.225 | | (vii) ACEI, n (%) | 28 (8.4) | 0 (0) | 0.382 | | (viii) ARB, n (%) | 127 (37.9) | 10 (52.6) | 0.230 |
| | Lesion factors | Late TLR(-) | Late TLR(+) | | | | (863 lesions) | (23 lesions) | |
| | Treated coronary location | | | 0.482 | | (i) LAD, n (%) | 397 (46.0) | 14 (60.9) | | | (ii) LCX, n (%) | 215 (24.9) | 3 (13.0) | | | (iii) RCA, n (%) | 249 (28.9) | 6 (26.1) | | | Bifurcation lesion, n (%) | 298 (34.5) | 10 (43.5) | 0.382 | | Calcified lesion | | | 0.109 | | (i) None, n (%) | 437 (50.9) | 14 (60.9) | | | (ii) Mild, n (%) | 154 (17.9) | 1 (4.3) | | | (iii) Moderate, n (%) | 113 (13.2) | 1 (4.3) | | | (vi) Severe, n (%) | 154 (17.9) | 7 (30.4) | | | Tortuous lesion | | | 0.761 | | (i) None, n (%) | 797 (92.8) | 22 (95.7) | | | (ii) Mild, n (%) | 24 (2.8) | 0 (0) | | | (iii) Moderate, n (%) | 25 (2.9) | 1 (4.3) | | | (vi) Severe, n (%) | 13 (1.5) | 0 (0) | | | Angulation lesion, n (%) | | | 0.428 | | (i) None (<45°), n (%) | 798 (93.1) | 23 (100.0) | | | (ii) Moderate (45°<90°), n (%) | 37 (4.3) | 0 (0) | | | (iii) Extreme n (>90°), n (%) | 22 (2.6) | 0 (0) | | | Thrombus in lesion, n (%) | 26 (3.0) | 3 (13.0) | 0.291 | | Ostial lesion, n (%) | 165 (19.1) | 4 (17.4) | 1.000 | | Ulceration, n (%) | 2 (0.2) | 0 (0) | 1.000 | | Aneurysm, n (%) | 10 (1.2) | 0 (0) | 1.000 | | Lesion type | | | 0.132 | | (i) A, n (%) | 87 (10.1) | 5 (21.7) | | | (ii) B1, n (%) | 206 (23.9) | 8 (34.8) | | | (iii) B2, n (%) | 50 (5.8) | 2 (8.7) | | | (vi) C, n (%) | 491 (56.9) | 8 (34.8) | | | Type B2/C lesion, n (%) | 541 (64.9) | 10 (43.5) | 0.059 | | Reference vessel diameter (mm) | 2.93±0.51 | 2.89±0.53 | 0.713 | | Lesion length (mm) | 27.7±17.1 | 25.3±20.2 | 0.561 | | Pre-procedure MLD (mm) | 0.74±0.50 | 0.75±0.59 | 0.926 | | Pre-procedure DS (%) | 74.7±15.7 | 74.9±17.3 | 0.938 | | Post-procedure MLD, in- stent (mm) | 2.49±0.43 | 2.55±0.40 | 0.509 | | Post-procedure MLD, in-segment (mm) | 2.12±0.51 | 2.26±0.55 | 0.216 | | Post-procedure DS, in- stent (mm) | 11.4±8.1 | 11.3±9.6 | 0.955 | | Post-procedure DS, in-segment (mm) | 21.0±11.3 | 20.5±10.9 | 0.825 |
|
|
TLR, target lesion revascularization; BMI, body mass index; kg, kilogram; PCI, percutaneous coronary intervention; CRF, chronic renal failure; FHx, family history; CAD, coronary artery disease; LV, left ventricle; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; WBC, white blood cell; GFR, glomerular filtration rate; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; CRP, C-reactive protein; DAPT, dual antiplatelet therapy; CCB, calcium channel blockers; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; MLD, minimal lumen diameter; DS, diameter stenosis.
# DAPT: combination of aspirin and clopidogrel.
|
